Skip to main content

Table 1 The distribution of baseline demographic and clinical characteristics according to sleep quality

From: The impact of impaired sleep quality on symptom change and future exacerbation of chronic obstructive pulmonary disease

Variables

Total

Bad sleeper

Good sleeper

P-

value

Number of patients,

n (%)

461(100.0)

228(49.5)

233(50.5)

 

Age (years)a

63.1 ± 8.2

64.3 ± 8.5

62.1 ± 9.0

0.016

Sexb

   

0.287

 Male

410(88.9)

199(87.3)

211(90.6)

 

 Female

52(11.1)

29(12.7)

22(9.4)

 

Educationb

   

0.116

 Primary school

158(34.3)

84(36.8)

74(31.8)

 

 Junior high school

189(41.0)

97(42.5)

92(39.5)

 

 High school

77 (16.7)

35(15.4)

42(18.0)

 

 University

37(8.0)

12 (5.3)

25 (10.7)

 

BMI (kg/m2)a

22.6 ± 3.1

22.3 ± 3.2

22.9 ± 3.4

0.096

Marry statusb

   

0.354

 married

351 (95.4)

219 (96.1)

222(95.2)

 

 unmarried

17(4.6)

9(3.9)

11 (4.8)

 

Smoking stateb

   

0.614

Current smoker

178(38.8)

84(36.9)

95(40.7)

 

Ex-smoker

210(45.6)

107(46.9)

103(44.2)

 

Non-smoker

72(16.6)

37(16.2)

35(16.0)

 

Biofuel exposureb

   

0.292

 Yes

169(36.7)

90(39.3)

79(34.1)

 

 No

292(63.3)

138(60.7))

154 (65.9)

 

Occupationalb

   

0.608

 Yes

182(39.4)

90(39.3)

79(39.5)

 

 No

279(60.6)

138 (60.7))

154 (60.5)

 

CATa

12.4 ± 6.8

14.6 ± 6.3

9.8 ± 6.0

<0.001

mMRCb

2 (1)

2(2)

2(1)

<0.001

 0–1

179(38.8)

71(31.1)

108(46.4)

0.001

 2–4

282(61.2)

157(68.9)

125(53.6)

 

CCQa

18.4 ± 8.2

20.3 ± 7.7

17.7 ± 7.4

<0.001

FEV1(L)c

1.4(0.90)

1.33(0.73)

1.49(0.99)

0.031

FEV1 (% predicted)c

54.40(31.2)

52.5(28.7)

56.0(31.7)

0.178

FEV1/FVCc

50.9(19.9)

47.1(19.7)

51.3(23.9)

0.030

Exacerbations

in the past yearc

0(1)

0(1)

0(1)

0.258

Exacerbations

in the past yearb

   

0.404

 0

230(49.9)

109(47.8)

121 (51.9)

 

 1

122(26.4)

59 (25.9)

63 (27.0)

 

 ≥ 2

109(23.7)

60 (26.3)

49(21.1)

 

GOLD groupb

   

<0.001

 A

81(17.6)

23(10.1)

58(24.9)

 

 B

195(42.3)

110(48.2)

85(36.5)

 

 C

25(5.4)

5(2.2)

20(8.6)

 

 D

160(34.7)

90(39.5)

70(30.0)

 

Treatmentb

   

0.012

 LAMA

91(19.7)

33(14.5)

58(24.9)

 

 LABA + ICS

62(13.4)

31(13.6)

31(13.3)

 

 LABA + LAMA

61(13.2)

37(16.2)

24(10.3)

 

 LABA + LAMA + ICS

217(47.1)

106(46.5)

111(47.6)

 

 Others

30(6.5)

21(9.2)

9(3.9)

 

PSQI scorea

5.8 ± 3.4

8.5 ± 2.7

3.2 ± 1.4

<0.001

 Sleep efficiencya

1.6 ± 1.1

2.3 ± 0.9

0.8 ± 0.6

<0.001

 Sleep qualitya

2 ± 1.4

3.2 ± 1.2

1.3 ± 0.6

<0.001

 Daily disturbancea

2.0 ± 1.0

2.9 ± 1.1

1.1 ± 0.7

<0.001

Risk of OSASb

   

0.892

 positive

93 (20.1)

46 (20.2)

47 (20.0)

0.890

 negative

368 (79.9)

182 (79.8)

186 (80.0)

 

Anxietyb

31 (6.8)

22 (9.8)

9 (3.8)

0.030

Depresionb

11 (2.4)

8 (3.3)

3 (1.1)

0.053

  1. aMean ± SD; bCounts with percentage are indicated; cMedian (IQR)
  2. Abbreviations: BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Diseas; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; FEV1, Forced Expiratory Volume in one second; FVC, Forced Vital Capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease. ICS, inhaled corticosteroids; IQR, interquartile range; LABA, long-acting β-2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified medical research council dyspnea scale; OSAS, obstructive sleep apnea syndrome ; PSQI, Pittsburgh sleep quality index.